Previous 10 |
home / stock / rlftf / rlftf news
Relief Therapeutics Holding AG ( OTCQB:RLFTF ) : 1H GAAP EPS of CHF0.004. More news on: Relief Therapeutics Holding AG, Earnings news and commentary, Read more ...
GENEVA, SWITZERLAND / ACCESSWIRE / September 15, 2020 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today an...
GENEVA, SWITZERLAND / ACCESSWIRE / September 4, 2020 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound aviptadil in advanced clinical development to treat severe COVID-19 patients, today announced the...
GENEVA, SWITZERLAND / ACCESSWIRE / August 31, 2020 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound Aviptadil in advanced clinical development to treat severe COVID-19 patients, today announced their...
Relief Therapeutics Holdings AG ( RLFTF ) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading under .10 per share. It was the rediscovery of the properties of their drug RLF-100, a propr...
The FDA has signed off on a Phase 2/3 clinical trial, AVICOVID-2, evaluating an inhaled formulation of Relief Therapeutics' ( OTCPK:RLFTF ) lead candidate RLF-100 (aviptadil) in moderately to severely ill COVID-19 patients to prevent progression to respiratory failure. More news on: ...
- Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung - RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polype...
Relief Therapeutics ( OTCPK:RLFTF ) and its partner U.S. partner NeuroRx announce that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill COVID-19 patients. More news on: Relief Therapeutics Holding AG, Healthcare stocks news, Re...
- Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites - Aviptadil is being develope...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...